Oxcarbazepine, often abbreviated OXC, is a chemical cousin of carbamazepine, one of the classic antiepileptic drugs that also established itself as a mainstay in the treatment of bipolar disorder. Structurally, oxcarbazepine is a keto analogue of carbamazepine, and it exerts its therapeutic effects primarily through its active metabolite, 10-hydroxycarbazepine, known as the monohydroxy derivative or MHD. This metabolite stabilizes hyperexcited neuronal membranes by blocking voltage-gated sodium channels, dampening the aberrant electrical firing that underlies both seizures and, in the psychiatric context, the pathological mood swings of mania. Because oxcarbazepine avoids some of the metabolic pitfalls of its parent compound, including the formation of reactive epoxide metabolites that have been implicated in carbamazepine hypersensitivity, clinicians have hoped it would offer a gentler profile. It is generally prescribed in selected clinical settings as an alternative or adjunctive option for patients with bipolar disorder who cannot tolerate first-line agents or who need additional mood stabilization.

Yet the skin remains a vulnerable organ system for this entire drug family. Antiepileptic drugs as a class are notorious for cutaneous adverse reactions, ranging from benign morbilliform rashes to the terrifying end of the spectrum occupied by severe cutaneous adverse reactions, or SCARs. These include Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms, known as DRESS. Stevens-Johnson syndrome and toxic epidermal necrolysis represent a continuum of the same disease process, in which an immune-mediated attack causes keratinocytes to die and the epidermis to separate from the dermis, producing blistering, skin sloughing, and mucosal involvement that can be life-threatening. Mortality in toxic epidermal necrolysis can reach double digits despite intensive care, and severity is often gauged with tools such as the SCORTEN score, while drug causality is assessed with instruments like the ALDEN algorithm and the RegiSCAR criteria. Against this backdrop, any report of skin reactions to oxcarbazepine deserves careful attention, particularly because reports describing OXC-associated cutaneous reactions specifically in patients with bipolar disorder have remained limited.

The Guangzhou team approached the problem with a retrospective descriptive design, combing through clinical records to identify twelve patients with bipolar disorder who had developed cutaneous reactions attributed to oxcarbazepine. The study was approved by the Medical Ethics Committee of the Affiliated Guangdong Second Provincial General Hospital of Jinan University, and written informed consent was obtained from all patients or their legal guardians. For each case, the researchers collected demographic characteristics, details of the medication regimen, the clinical features of the skin eruption, and the treatment outcomes. The diagnosis of bipolar disorder was established according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, ensuring a diagnostically homogeneous cohort in which the drug, rather than diagnostic heterogeneity, was the variable of interest.

The timing of the reactions emerged as one of the most striking patterns in the data. Onset of cutaneous reactions occurred mainly within the first two weeks of treatment, a temporal signature that mirrors what is known about hypersensitivity reactions to aromatic antiepileptic drugs generally. This early window matters enormously for clinical practice, because it defines the period during which patients and their families need to be most vigilant. A rash appearing in the first fortnight of oxcarbazepine therapy should never be dismissed as a trivial irritation; it demands prompt evaluation and, in many cases, immediate discontinuation of the drug. The two-week signal also aligns with the immunology of delayed-type drug hypersensitivity, in which sensitization to a drug or its metabolites typically requires days to weeks before T-cell-mediated pathology becomes clinically visible on the skin.

In terms of presentation, the most common form was a generalized eruption, meaning a rash spreading across large areas of the body, followed by localized eruptions confined to specific regions. One patient among the twelve was diagnosed with Stevens-Johnson syndrome, the severe blistering disorder that constitutes a dermatological emergency. That single case is the most sobering element of the series, a reminder that even a drug marketed partly on its improved tolerability can, in susceptible individuals, trigger the full machinery of a severe cutaneous adverse reaction. The patient with Stevens-Johnson syndrome was among three patients in the series who were receiving lamotrigine concurrently, and the authors note that mixed drug attribution could not be excluded in these cases. Lamotrigine itself carries a well-known risk of severe skin reactions, particularly when titrated rapidly, so the presence of both drugs complicates the causal picture and illustrates a perennial challenge in psychopharmacology: patients with bipolar disorder frequently take combinations of medications, and disentangling which agent is responsible for an adverse event requires careful pharmacovigilance.

The good news from the series is that the outcomes were favorable. Clinical improvement was observed after discontinuation of oxcarbazepine and supportive management, a pattern consistent with the natural history of most drug-induced cutaneous reactions, which typically resolve once the offending agent is cleared. Supportive management for severe reactions can involve wound care, fluid and electrolyte management, pain control, and in the most serious cases interventions such as intravenous immunoglobulin, though the source material does not specify which supportive measures were used in individual patients. The essential clinical algorithm, however, is clear: early recognition, immediate drug withdrawal, and supportive care form the backbone of treatment for antiepileptic-induced skin reactions, and the Guangzhou experience reinforces that approach in the specific context of bipolar disorder.

The authors are appropriately cautious about what their study can and cannot show. With only twelve patients, a retrospective design, and no comparison group, the findings must be interpreted descriptively. They cannot be used to estimate the true incidence of oxcarbazepine-associated skin reactions, to establish causality with certainty, or to identify independent risk factors for developing them. Retrospective case series are hypothesis-generating by nature; they map the terrain of a clinical problem without quantifying its frequency. The researchers explicitly call for larger prospective studies to further characterize these reactions, work that would ideally include systematic skin assessment at defined time points, pharmacogenomic testing, and comparison groups of patients taking oxcarbazepine without reactions. Such studies could eventually clarify whether known genetic risk factors for carbamazepine hypersensitivity, such as certain human leukocyte antigen alleles, also predispose patients to oxcarbazepine reactions, a question of intense interest given the structural relationship between the two drugs.

For clinicians treating bipolar disorder, the practical takeaways are nonetheless actionable today. Oxcarbazepine remains a legitimate option in selected patients, but prescribers should counsel patients explicitly about skin symptoms before the first prescription, emphasizing that any rash, blistering, mucosal ulceration, or fever with skin changes in the first weeks of therapy warrants urgent medical contact. The first two weeks deserve heightened vigilance, and concomitant lamotrigine should prompt extra caution in attribution and monitoring. For patients, the study is a reminder that psychiatric medications, like all drugs, carry physical as well as psychological side effects, and that the skin can serve as an early warning system. For researchers, the twelve cases from Guangzhou provide a descriptive foundation on which larger, prospective investigations can now build, moving the field from anecdote toward the incidence estimates and risk-factor profiles that would allow truly personalized prescribing decisions in bipolar disorder.

Subject of Research: Cutaneous adverse reactions associated with oxcarbazepine treatment in patients with bipolar disorder

Article Title: Clinical features of oxcarbazepine-associated cutaneous reactions in patients with bipolar disorder: a retrospective case series

Article References: Huang, Y., Xue, K., Fan, C., Ren, X., & Zeng, X. (2026). Clinical features of oxcarbazepine-associated cutaneous reactions in patients with bipolar disorder: a retrospective case series. BMC Psychiatry. https://doi.org/10.1186/s12888-026-08621-w

Image Credits: AI Generated

DOI: 10.1186/s12888-026-08621-w

Keywords: oxcarbazepine, bipolar disorder, cutaneous reactions, Stevens-Johnson syndrome, antiepileptic drugs, severe cutaneous adverse reactions, lamotrigine, drug hypersensitivity, case series, psychopharmacology, drug safety, dermatology

DRESS/DIHS is one of the most serious delayed-type adverse drug reactions encountered in clinical medicine. It is characterized by a widespread skin eruption, fever, systemic inflammation, involvement of internal organs such as the liver, hematologic abnormalities including atypical lymphocytes, and, in many cases, reactivation of human herpesvirus 6, or HHV-6. The syndrome typically develops two to six weeks after exposure to the culprit drug, a latency that distinguishes it from immediate hypersensitivity reactions. Mortality is significant, particularly when liver involvement is severe, and recognition depends on scoring systems such as RegiSCAR that integrate rash morphology, fever, lymphadenopathy, blood count abnormalities, organ involvement, and viral reactivation. In immunocompetent patients, the diagnostic constellation is usually recognizable, but the syndrome’s presentation can be substantially altered in patients whose immune systems have been profoundly suppressed by chemotherapy.

CPX-351, marketed as Vyxeos, is a dual-drug liposomal encapsulation designed to optimize the synergistic molar ratio of cytarabine to daunorubicin and to prolong their exposure within the plasma. It is approved for treatment-related acute myeloid leukemia and acute myeloid leukemia with myelodysplasia-related changes, populations in which intensified traditional induction regimens carry prohibitive toxicity. Skin eruptions are common adverse events with CPX-351, and one of the most frequent cutaneous findings in these patients is toxic erythema of chemotherapy, or TEC, a benign and self-limited eruption that typically affects the hands, intertriginous areas, and trunk within days of drug exposure. Distinguishing TEC from an evolving DRESS/DIHS-like reaction is difficult, and the new case illustrates precisely how the two conditions can overlap in their earliest phases.

In the reported patient, the cutaneous story began with an early eruption localized to the intertriginous areas and trunk, a distribution and timing initially compatible with toxic erythema of chemotherapy. Had the eruption followed the usual course, it would have been expected to stabilize and resolve without intervention. Instead, the clinical picture deteriorated. The patient developed recurrent fevers, and the eruption progressed to generalized erythema covering more than 90 percent of his body surface area. Accompanying features included lymphadenopathy, the appearance of atypical lymphocytes in the peripheral blood, and elevation of liver enzymes, each of which is a recognized component of the DRESS/DIHS diagnostic framework. Taken together, these findings shifted the clinical suspicion away from benign toxic erythema and toward a systemic drug hypersensitivity syndrome.

Several laboratory investigations provided pivotal diagnostic clues. Most strikingly, quantitative polymerase chain reaction demonstrated a markedly elevated HHV-6 DNA level of 1.2 million copies per milliliter of blood. HHV-6 reactivation is considered a signature feature of classic DRESS/DIHS, occurring in the majority of typical cases, and its detection in this severely lymphopenic patient served as a strong corroborating marker of the syndrome. At the same time, the case defied several conventional expectations. The patient had severe chemotherapy-induced lymphopenia, there was no peripheral eosinophilia, skin histology revealed inconspicuous dermal eosinophils, and serum thymus and activation-regulated chemokine, known as TARC and often used as a biomarker of DRESS/DIHS, was at a normal level. The authors emphasize that these deviations are precisely what made the diagnosis so difficult, since eosinophilia and elevated TARC are among the criteria clinicians most commonly rely upon.

A skin biopsy provided additional support for the diagnosis. Histopathologic examination showed interface dermatitis with superficial perivascular lymphocytic infiltration, a pattern consistent with a delayed hypersensitivity reaction rather than the necrotic keratinocytes and eccrine involvement more characteristic of toxic erythema of chemotherapy. Interface dermatitis, in which lymphocytes attack the basal layer of the epidermis, is a histologic hallmark seen in many drug-induced eruptions, including DRESS/DIHS, and its identification helped consolidate the clinical and laboratory findings into a coherent diagnosis despite the absence of eosinophils in the dermal infiltrate.

Treatment with systemic prednisolone produced a rapid and convincing response. The patient’s fever resolved promptly, appetite improved, the extensive skin lesions began to heal, atypical lymphocytes disappeared from the circulation, and HHV-6 DNA became undetectable. The temporal relationship between corticosteroid initiation and the simultaneous resolution of inflammatory, cutaneous, and virologic abnormalities is characteristic of DRESS/DIHS and further reinforced the diagnostic conclusion. Importantly, the patient was subsequently able to proceed to conditioning therapy and umbilical cord blood transplantation, meaning that recognition and treatment of the hypersensitivity reaction did not derail his definitive leukemia management.

Attribution of the reaction to CPX-351 required careful weighing of alternatives, and the authors frame the association as possible rather than definitive. The temporal relationship between CPX-351 administration and the onset of the reaction was the principal basis for implicating the drug, but the authors explicitly note that toxic erythema of chemotherapy and concomitant medications represented important alternative considerations. Patients with acute myeloid leukemia typically receive multiple supportive agents, including antimicrobials, antifungals, and antivirals, several of which are themselves recognized causes of DRESS/DIHS. In addition, the leukemia itself and its complications can produce fever, rash, hepatic dysfunction, and lymphadenopathy. The heterogeneity of the clinical environment in hematology patients means that drug causality assessment in this population is intrinsically uncertain, and the report’s cautious language reflects this reality.

Beyond its immediate clinical message, the case carries broader implications for how DRESS/DIHS is understood and diagnosed. Classical descriptions assume a relatively intact immune system capable of mounting the full hypersensitivity phenotype, including expansion of drug-specific T cells, eosinophil recruitment through interleukin-5, and elevated TARC production by activated lymphocytes. A patient with profound chemotherapy-induced lymphopenia lacks the cellular substrate for many of these features, and the reported case demonstrates that the syndrome can nonetheless develop in this setting. This suggests that current diagnostic criteria, which award points for eosinophilia, atypical lymphocytes, and lymphadenopathy, may underdiagnose DRESS/DIHS in severely immunocompromised patients. The authors propose that HHV-6 reactivation may serve as a particularly valuable diagnostic marker when eosinophilia is absent, since viral reactivation appears to depend on mechanisms that can persist despite lymphocyte depletion.

The report also offers practical guidance for clinicians who treat high-risk acute myeloid leukemia with CPX-351. Skin eruptions during therapy should not automatically be dismissed as toxic erythema of chemotherapy, particularly when they progress beyond the typical distribution, persist or worsen after the expected time course, or are accompanied by recurrent fever, lymphadenopathy, hepatic enzyme elevation, or atypical lymphocytes. In such circumstances, measurement of HHV-6 DNA and consideration of a DRESS/DIHS-like reaction are warranted even in the face of severe lymphopenia and absent eosinophilia. Early recognition matters because untreated DRESS/DIHS can progress to fulminant hepatic failure and death, while timely systemic corticosteroids, as demonstrated in this patient, can produce rapid clinical improvement and allow the underlying leukemia treatment plan, including allogeneic transplantation, to continue on schedule. As CPX-351 use expands worldwide, the authors suggest that clinicians maintain heightened awareness that this liposomal chemotherapy regimen, like many other drugs, may in rare cases trigger systemic hypersensitivity, and that its cutaneous and systemic fingerprints may look different in the immunosuppressed host than in the patients in which the syndrome was first described.

Subject of Research: Possible CPX-351-associated DRESS/DIHS-like drug hypersensitivity reaction during severe lymphopenia in acute erythroid leukemia

Article Title: Possible CPX-351-associated drug reaction with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome-like reaction during severe lymphopenia

Article References: Bamba, S., Kanda, J., Hada, M., Kubota, Y., Nakajima, S., Nomura, T., Fukutome, T., Tsuji, K., & Takaori-Kondo, A. (2026). Possible CPX-351-associated drug reaction with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome-like reaction during severe lymphopenia. Annals of Hematology. https://doi.org/10.1007/s00277-026-07282-9

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07282-9

Keywords: CPX-351, DRESS, DIHS, HHV-6, acute myeloid leukemia, drug hypersensitivity, lymphopenia, skin eruptions, TARC, interface dermatitis, toxic erythema of chemotherapy, Annals of Hematology